Kinney W K, Alvarez R D, Reid G C, Schray M F, Soong S J, Morley G W, Podratz K C, Shingleton H M
Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, Minnesota 55905.
Gynecol Oncol. 1989 Sep;34(3):258-62. doi: 10.1016/0090-8258(89)90156-x.
In a retrospective study, 185 patients with previously untreated stage IB or IIA (International Federation of Gynecology and Obstetrics) squamous cell carcinoma of the cervix were found to have pelvic nodal metastasis at the time of Wertheim hysterectomy and bilateral pelvic lymphadenectomy. Of these patients, 103 received adjuvant whole-pelvis irradiation and 82 received no adjuvant therapy. Median dose of pelvic irradiation was 5000 cGy. Among the irradiated patients, in 75% the dose was 5000 cGy or greater. Matching irradiated and nonirradiated patients according to stage, tumor size, and number and location of positive nodes yielded 60 pairs. Mean length of follow-up was 3.9 years for the 60 irradiated patients and 5.8 years for the non-irradiated patients. Kaplan-Meier overall and cancer-specific survival estimates for the two groups were not significantly different (P greater than 0.30). During the follow-up period, 21 surgery-only patients and 22 patients treated with adjuvant radiotherapy had recurrence, but adjuvant radiotherapy decreased the proportion of recurrences occurring in the pelvis alone--27% compared with 67% in the surgery-only group (P = 0.01).
在一项回顾性研究中,185例先前未经治疗的国际妇产科联盟(International Federation of Gynecology and Obstetrics)IB期或IIA期宫颈鳞状细胞癌患者在进行韦特海姆子宫切除术及双侧盆腔淋巴结清扫术时被发现有盆腔淋巴结转移。这些患者中,103例接受了辅助性全盆腔放疗,82例未接受辅助治疗。盆腔放疗的中位剂量为5000厘戈瑞(cGy)。在接受放疗的患者中,75%的患者剂量为5000 cGy或更高。根据分期、肿瘤大小以及阳性淋巴结的数量和位置对接受放疗和未接受放疗的患者进行匹配,得到60对。60例接受放疗患者的平均随访时间为3.9年,未接受放疗患者的平均随访时间为5.8年。两组患者的Kaplan-Meier总生存率和癌症特异性生存率估计值无显著差异(P大于0.30)。在随访期间,21例仅接受手术治疗的患者和22例接受辅助放疗的患者出现复发,但辅助放疗降低了仅在盆腔出现复发的比例——分别为27%和67%(P = 0.01)。